Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;101(4):929-931.
doi: 10.1007/s00277-021-04613-w. Epub 2021 Jul 24.

Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis

Giovanni Caocci  1   2 , Olga Mulas  3   4 , Daniela Mantovani  3 , Alessandro Costa  4 , Andrea Galizia  4 , Luca Barabino  4 , Marianna Greco  3 , Roberta Murru  3 , Giorgio La Nasa  3   4
Affiliations

Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis

Giovanni Caocci et al. Ann Hematol. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Carneiro DC, Sousa JD, Monteiro-Cunha JP. The COVID-19 vaccine development: a pandemic paradigm. Virus Res. 2021;301:198454. doi: 10.1016/j.virusres.2021.198454. - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Salute M della. Guidelines of the strategic plan on COVID-19 vaccines approved by parliament [Internet]. [cited 2021 Jun 2]. Available from: https://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&me.... Accessed 6 April 2021
    1. Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(12):1262–1271. doi: 10.1002/ajh.24592. - DOI - PubMed
    1. Arana Yi C, Tam CS, Verstovsek S. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol Lond Engl. 2015;11(5):719–733. doi: 10.2217/fon.14.272. - DOI - PMC - PubMed